In precision vaporizer circuits, halothane veterinary grade API is handled as a neat, stabilized volatile liquid rather than a conventional tablet or solution. The neat liquid is charged into agent-specific plenum vaporizers where fresh carrier gas is split between a bypass channel and a saturated vaporising chamber; the resulting output is expressed as percent v/v in inspired gas. The active molecule is 2-bromo-2-chloro-1,1,1-trifluoroethane, with boiling point 50.2°C, saturated vapour pressure 243 mmHg at 20°C, density 1.87 g/mL, and molecular weight 197.38. The veterinary-grade monograph requires assay within 98.0% to 102.0% w/w and thymol stabiliser content between 0.008% and 0.012% w/w, as specified in Ph. Eur. monograph 0863 and equivalent BP (Vet) provisions. Thymol is not a preservative in the conventional aqueous sense; it is added to retard acid-generating degradation during storage and repeated sump exposure.

Clinical inhalant anaesthesia in dog, horse, pig, cat, laboratory rodent, and rabbit uses dial settings from 0.5% to 5.0% v/v depending on induction versus maintenance. Published minimum alveolar concentration values place surgical maintenance around 1.0–1.5 MAC, with canine MAC commonly cited near 0.87%, equine MAC near 0.88%, feline MAC near 1.19%, and rat MAC near 1.10%. The relatively high blood/gas partition coefficient of approximately 2.5 and oil/gas partition coefficient near 224 produce slower equilibration with cerebral tissue than agents such as isoflurane, requiring longer wash-in and longer elimination after discontinuation. In production-scale veterinary hospital use, the main process conflicts are temperature drift in the vaporising chamber, liquid entrainment during overfilling, and failure to return the dial to zero before moving the vaporizer. Temperature-compensated vaporizers are designed for the 18–35°C ambient range; operation below 18°C reduces output whereas operation above 35°C increases the delivered concentration because the saturated vapour pressure of halothane rises steeply with temperature. The vaporizer sump must remain upright; inversion or shaking can flood the bypass channel and produce uncontrolled high output.

Terminal use is therefore inhalation solution only; the API is not diluted into aqueous media for vaporisation. Waste gas scavenging and active charcoal adsorption are mandatory because the vapour is an occupational exposure hazard; NIOSH has recommended trace gas levels in operating rooms not exceed 2 ppm as a 60-minute ceiling for halogenated anesthetics. Halothane is contraindicated in malignant hyperthermia–susceptible pigs and certain dog lines; induction and maintenance must be adjusted for hypotension and dose-dependent respiratory depression. For inventory control, the liquid is filled into amber glass bottles with PTFE-lined closures; polycarbonate and acrylic contact surfaces are incompatible because halothane causes stress cracking and permeation.

What Limits Intravenous Use of Halothane Veterinary API in Compounded Lipid Emulsions?

Intravenous administration of halothane in veterinary species has been explored in experimental lipid emulsion vehicles but remains outside licensed veterinary labelling. The API is poorly water soluble; published water-solubility values cluster near 0.3–0.5% w/v at 20°C, which is unsuitable for direct aqueous injection. In theory, a sterile lipid emulsion or a surfactant-stabilised nanoemulsion can carry small amounts of halothane, but the high vapour pressure of 243 mmHg at 20°C and boiling point 50.2°C create losses during high-shear homogenization and terminal sterilisation. Compounding under USP 797 conditions requires aseptic handling, sterile filtration through 0.22 μm membranes, and absence of particulate matter; volatile lipophilic drugs may coalesce on filter surfaces or partition into plastic components. Published data for this specific configuration is limited; documented veterinary use has not progressed beyond experimental laboratory formulations. The principal limitation is not sterility but dose accuracy: headspace GC assay must be performed immediately after preparation because the effective halothane concentration in an emulsion at 37°C declines as the drug escapes into the gas phase. Cardiorespiratory depression and solvent effects of the lipid vehicle further narrow the therapeutic window. Consequently, intravenous use is not a routine downstream application and must be treated as an investigational compounding route with no compendial monograph.

If a compounded injectable is attempted, process parameters that require control include homogenization rotor speed, cooled jacket temperature maintained below 25°C, and headspace volume in the final container. Nitrogen overlay and sealed borosilicate glass vials reduce evaporative loss; elastomer closures should be PTFE faced because halothane extracts plasticizers from conventional rubber. Terminal sterilisation by autoclave is not feasible because the drug boils at 50.2°C; sterile filtration remains the only viable method but may fail if oil droplet size exceeds the filter rating. There is no pharmacopoeial acceptance value for halothane emulsion droplet diameter, and batch-to-batch variance in the lipid source alters partitioning. Injection is therefore omitted from standard veterinary anaesthesia protocols and is referenced only in controlled research settings.

Because halothane exists as a low-boiling liquid at normal room temperature, powder and granule dosage forms are not intrinsic routes of administration and are technically feasible only through physical adsorption onto a porous solid carrier. Porous carriers such as microcrystalline cellulose, colloidal silicon dioxide, mesoporous silica, and beta-cyclodextrin have been studied for volatile liquid immobilisation. The maximum loading before external liquid appears is governed by carrier pore volume and BET surface area; no pharmacopoeial monograph defines an acceptance value for halothane adsorbed onto these materials. The adsorption process itself generates heat of condensation, and blender shear adds further thermal input. If the bed temperature reaches 30–35°C, the surface partial pressure of halothane rises, leading to evaporative loss and non-uniform content. A jacketed blender with chilled wall temperature below 25°C and relative humidity below 40% is therefore required. Water vapour competes for adsorption sites and can displace halothane from silica and cyclodextrin cavities, so aqueous wet granulation is destructive to the formulation. Dry granulation by roller compaction is more compatible only if the rolls are chilled to offset compaction heat; otherwise localized die wall temperatures can exceed 30°C and strip the adsorbate. Conventional loss on drying at 105°C is not applicable because halothane will be lost with moisture; assay must be performed by headspace GC after complete dissolution of the carrier. Terminal powders and granules containing halothane are investigational and do not represent a registered veterinary product category.

Thermal Loss Profiles in Halothane-Filled Hard Gelatin Capsules

Hard gelatin capsule and tablet presentation for halothane is limited by the API’s volatility and the thermal and mechanical energy inevitably introduced by capsule filling and tablet compression. Gelatin capsules contain 13–16% w/w moisture; this moisture plasticises the shell but also creates an aqueous microclimate at the shell–fill interface. Halothane, as a poorly water-soluble volatile liquid, migrates through the gelatin film rather than remaining immobilised on an adsorbate. Band-sealed capsules reduce leakage, but the vapour pressure at 20°C remains 243 mmHg, and diffusion through the shell can occur within hours unless the capsules are stored at 4°C in impermeable aluminium foil blisters. Tablet compression is an even more aggressive process: direct compression of a halothane-loaded adsorbate at press forces above 10 kN can generate localized die wall temperatures above 30°C, causing evaporative loss and die-wall accumulation. There is no recognized veterinary halothane tablet or capsule monograph, and no compendial acceptance criteria for content uniformity exist for such presentations. Published data for this specific configuration is limited.

Where a protocol demands oral or gastric administration in a wildlife or zoological setting, a freshly prepared adsorbate-filled capsule may be considered only if the capsule is stored at 2–8°C and administered within 24 h; assay loss should be verified by headspace GC before and after filling. This is an extemporaneous use and not a licensed terminal dosage form. Tablets and capsules are therefore excluded from routine production planning for halothane veterinary grade API.

During bulk compounding of liquid premixes for syringe pump or vaporizer transfer systems, the API is handled as a neat, stabilized liquid rather than a diluted stock; any dilution into organic solvents is restricted to research use because the vapour pressure, solubility, and safety profile change with co-solvent. Halothane is miscible with ethanol, diethyl ether, chloroform, and fixed oils, but only slightly soluble in water. Dilution in ethanol or oil is not acceptable for inhalation vaporizer output because vaporizer calibration assumes neat halothane with the density and vapour pressure parameters stated in the monograph. Transfer lines must be chilled and nitrogen-overlaid to prevent vapour lock, because the boiling point is 50.2°C and the saturated vapour pressure at 20°C is 243 mmHg. Peristaltic pumping through flexible tubing may create vapour cavities on the suction side; therefore rigid stainless-steel or PTFE tubing is preferred for bulk transfer. Containers should be amber glass with PTFE-lined closures; polycarbonate, acrylic, and PVC are unsuitable because halothane can extract plasticizers and cause stress cracking. Terminal premix solutions for non-inhalation routes have no approved veterinary formulation; such mixtures are used in analytical preparation or investigational pharmacokinetic studies rather than licensed treatment.

Analytical Reference Materials and Headspace Gas Chromatography Calibration

Veterinary-grade halothane is used as a neat liquid reference material for headspace gas chromatography and gas chromatography with flame ionisation detection in residue and vaporiser output verification. The analytical demand is not primarily therapeutic but is a downstream use in quality control laboratories supporting veterinary anaesthesia equipment and environmental monitoring. A typical headspace method equilibrates the sample at 40°C for 30 min and injects a split volume onto a 30 m × 0.32 mm × 1.8 μm poly(6% cyanopropylphenyl/94% dimethylpolysiloxane) column; hydrogen or helium carrier gas is used. The retention time of halothane and the thymol stabiliser must resolve, and the thymol limit of 0.008% to 0.012% w/w is used as a system-suitability marker because it confirms that the sample has not undergone thermal degradation before injection. Calibration standards are prepared gravimetrically in headspace vials and sealed immediately; vial equilibration temperature must remain below 50°C to avoid approaching the boiling point and pressure shifts. This application requires no formulation into tablets, capsules, granules, premix, or injection; the API is consumed as a neat liquid standard for method validation and equipment calibration. Batch-to-batch variance in thymol content and trace halocarbon impurities can shift relative response factors, so each new lot must be qualified against a certified reference standard traceable to Ph. Eur. 0863.